NASDAQ
No price data available for this timeframe.
GridAI Technologies Corp. functions as a clinical-stage biopharmaceutical enterprise primarily dedicated to developing precise, locally-acting treatments for various digestive system ailments. Its core activity involves researching and advancing therapeutic solutions specifically designed for patients with gastrointestinal diseases. The company's pipeline features several key drug candidates, including Latiglutenase, Capeserod, Adrulipase, and Niclosamide. GridAI Technologies was established on January 30, 2014, and maintains its principal offices in Boca Raton, Florida.
Open
$3.99
Previous Close
$3.85
Day High
$3.99
Day Low
$3.81
52 Week High
$6.93
52 Week Low
$1.73